Biogen announced positive topline results from its Phase 2 CELIA study of diranersen, an investigational therapy targeting tau protein in early Alzheimer's disease. The study showed robust reductions in tau pathology and a slowing of cognitive decline, especially at the lowest dose, although it did not meet its primary endpoint on dose response. The safety profile was consistent with earlier studies. Based on these findings, Biogen plans to advance diranersen to registrational development and will present detailed data at upcoming scientific conferences.
Biogen reported Phase 2 trial results for diranersen, a tau-targeting therapy for early Alzheimer’s, showing cognitive benefits and reduced tau biomarkers despite missing the primary endpoint. The drug slowed cognitive decline across doses, especiall...
Biogen has finalized its acquisition of Apellis Pharmaceuticals, gaining full ownership of two commercial products, EMPAVELI® and SYFOVRE®, which generated $689 million in revenue in 2025. This deal enhances Biogen's growth prospects and expands its ...
